Ashish Noronha

Ashish Noronha

Auto-generated profile, based on publicly available information

Ashish Noronha

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether the treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in EGFRi-treated patients presenting residual disease, we observed upregulation of GAS6, whereas ablation of GAS6's receptor, AXL, eradicated resistance. Reciprocally, AXL overexpression enhanced DTP survival and accelerated the emergence of T790M, an EGFR mutation typical to resistant cells. Mechanistically, AXL induces low-fidelity DNA polymerases and activates their organizer, RAD18, by promoting neddylation. Metabolomics uncovered another hypermutator, AXL-driven activation of MYC, and increased purine synthesis that is unbalanced by pyrimidines. Aligning anti-AXL combination treatments with the transition from DTPs to resistant cells cured patient-derived xenografts. Hence, similar to bacteria, tumors tolerate therapy by engaging pharmacologically targetable endogenous mutators. Significance: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators are activated in drug-treated cells, and this heralds tolerance. Blocking the process prevented resistance in xenograft models, which offers new treatment strategies. This article is highlighted in the In This Issue feature, p. 2483

30 January 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
LRLee Roth
Lee Roth
SSSwati Srivastava
Swati Srivastava
MLMoshit Lindzen
Moshit Lindzen
ASAldema Sas-Chen
Aldema Sas-Chen
MSMichal Sheffer
Michal Sheffer
YYYosef Yarden
Yosef Yarden
LAD1 coordinates EGF-stimulated changes in the cytoskeleton to support aggressive phenotypes in breast cancers.

15 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ATAriel Tennenhouse
Ariel Tennenhouse
LKLev Khmelnitsky
Lev Khmelnitsky
RKRazi Khalaila
Razi Khalaila
NYNoa Yeshaya
Noa Yeshaya
ANAshish Noronha
Ashish Noronha
SFSarel Fleishman
Sarel Fleishman
Humanization is an essential step in developing animal-derived antibodies into therapeutics, and approximately one third of approved antibodies have been humanized. Conventional humanization approaches graft the complementarity-determining regions (CDRs) of the animal antibody onto several homologous human frameworks. This process, however, often drastically lowers stability and antigen binding, demanding iterative mutational fine-tuning to recover the original antibody properties. Here, we present Computational hUMan AntiBody design (CUMAb), a web-accessible method that starts from an experimental or model antibody structure, systematically grafts the animal CDRs on thousands of human frameworks, and uses Rosetta atomistic simulations to rank the designs by energy and structural integrity ( http://CUMAb.weizmann.ac.il ). CUMAb designs of five independent antibodies exhibit similar affinities to the parental animal antibody, and some designs show marked improvement in stability. Surprisingly, nonhomologous frameworks are often preferred to the highest-homology ones, and several CUMAb designs that use different human frameworks and differ by dozens of mutations are functionally equivalent. Thus, CUMAb presents a general and streamlined approach to optimizing antibody stability and expressibility while increasing humanness.

4 April 2023
Verified
Other
Open access
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

4 April 2023
Verified
Other
Open access
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer